The Board of Nabi Biopharmaceuticals Establishes Ratio for Reverse Stock Split

The Board of Nabi Biopharmaceuticals Establishes Ratio for Reverse Stock Split

ROCKVILLE, Md., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals
(Nasdaq:NABI) today announced that its board of directors (the "Board") has
established a ratio of one share-for-every six shares of the outstanding
common stock for Nabi's proposed reverse stock split of all outstanding shares
of common stock. Nabi anticipates that the reverse stock split will be
effective as of 4:59 p.m., Eastern Time, on November 8, 2012 (the "Effective
Time") and will be reflected in the trading price of Nabi common stock at the
opening of trading on November 9, 2012.

In connection with the reverse stock split at the established ratio of
one-for-six, the number of Nabi shares to be issued in connection with the
proposed business combination transaction between Nabi and Biota Holdings
Limited (ASX:BTA.AX) will be adjusted so that if the transaction is completed,
each ordinary share of Biota capital stock will be transferred to Nabi in
exchange for 0.1249630125 of a share of Nabi common stock (not taking into
account that Nabi will not issue fractional shares in connection with the
reverse stock split and will, instead pay cash in lieu of issuing fractional
shares to stockholders of record).

The establishment of the reverse stock split ratio followed the reconvened
October 22, 2012 special meeting of Nabi stockholders at which the
stockholders adopted an amendment to Nabi's Restated Certificate of
Incorporation to effect a reverse stock split at a specific ratio to be
determined by the Board in its sole discretion at one of the following five
reverse stock split ratios: one-for-four, one-for-five, one-for-six,
one-for-seven and one-for-eight.

No fractional shares of Nabi common stock will be issued in connection with
the reverse stock split. A stockholder of record holding a fractional share as
a result of the reverse stock split will receive a cash payment (without
interest) in lieu of the issuance of any such fractional share equal to (i)
such fractional share interest to which the stockholder would otherwise be
entitled, after taking into account all shares of common stock then held by
the stockholder immediately prior to the Effective Time, multiplied by (ii)
the average closing sale price of Nabi common stock for the 10 trading days
immediately prior to the Effective Time as officially reported by the Nasdaq
Global Select Market.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals, headquartered in Rockville, Maryland, is a
biopharmaceutical company that has focused on the development of vaccines
addressing unmet medical needs, including nicotine addiction. Its sole product
currently in development is NicVAX^® (Nicotine Conjugate Vaccine), an
innovative and proprietary investigational vaccine for the treatment of
nicotine addiction and prevention of smoking relapse based on patented
technology. For additional information about Nabi Biopharmaceuticals, please
visit www.nabi.com.

Forward-Looking Statements

Statements set forth above that are not strictly historical are
forward-looking statements. You can identify these forward-looking statements
because they involve our expectations, intentions, beliefs, plans,
projections, anticipations, or other characterizations of future events or
circumstances. These forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that may cause actual
results to differ materially from those in the forward-looking statements as a
result of any number of factors. These factors include, but are not limited
to, risks that are more fully discussed in Nabi's Annual Report on Form 10-K,
as amended, for fiscal year ended December 31, 2011, Quarterly Reports on Form
10-Q for the quarters ended March 31 and June 30, 2012 and definitive proxy
statement for Nabi stockholders special meeting filed with the SEC on August
7, 2012, as supplemented by the supplement dated September 25, 2012, under the
captions "Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Statement" and elsewhere in such documents. We do not undertake to update any
of these forward-looking statements or to announce the results of any
revisions to these forward-looking statements except as required by law.

CONTACT: Nabi Investor Relations
         301-770-3099
         www.nabi.com
        
         Morrow & Co., LLC
         Attn: Joe Mills
         203-658-9400
 
Press spacebar to pause and continue. Press esc to stop.